Mutant p53 Associates with Human Equilibrative Nucleoside 1 Upregulation and Better Response to Adjuvant Gemcitabine in Intrahepatic Cholangiocarcinoma Patients
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26115259 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marzia Deserti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: Deoxycytidine, Cholangiocarcinoma, Tumor Suppressor Protein p53, Equilibrative Nucleoside Transporter 1. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Healt.
Abstract (Originalsprache)
The prognostic and predictive role of the human equilibrative nucleoside transporter 1 (hENT-1) has emerged in different cancer types, including intrahepatic cholangiocarcinoma (iCCA), but the mechanisms regulating its expression are poorly understood. Here, we investigated the link between p53 status and hENT-1 regulation in 38 iCCA patients and cell line models; the predictive role of p53 status in response to adjuvant gemcitabine was also investigated. A positive association between mutant p53 cells and hENT-1 expression was observed in iCCA tissue samples; furthermore, patients receiving adjuvant gemcitabine and expressing mutant p53 cells > 4% in tumor tissue had a longer disease-free survival (DFS) than patients expressing mutant p53 cells ≤ 4% (median 18.5 vs. 6 months, p = 0.0229). In iCCA cell line models, transient knockdown of mutant p53 resulted in a decrease in hENT-1 mRNA and protein expression; similarly, restoration of wild-type p53 function induced a significant reduction in hENT-1 mRNA and protein expression. Overall, these findings support a role of p53 status in the regulation of hENT-1 expression, suggesting an opposite effect (activating versus repressive) of mutant and wild-type p53 protein. Furthermore, although the present study should be considered as preliminary, our findings suggest a predictive role of p53 status in iCCA patients treated with gemcitabine, thus deserving future investigations in additional cohorts of cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- Pathology Unit, Santa Maria delle Croci Ravenna Hospital, 48121 Ravenna, Italy.
- Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
ORCID-Profile: Andrea Palloni, Deborah Malvi, Alessio Degiovanni, Simone Rimedio, Chiara Delbaldo, Simona Tavolari
Förderung
- Italian Ministry of Healt
Zitieren
APA
Deserti, M., Relli, V., Palloni, A., Vasuri, F., Malvi, D., Degiovanni, A., Rimedio, S., Delbaldo, C., Deiana, C., Brandi, G., & Tavolari, S. (2025). Mutant p53 Associates with Human Equilibrative Nucleoside 1 Upregulation and Better Response to Adjuvant Gemcitabine in Intrahepatic Cholangiocarcinoma Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115259
Vancouver
Deserti M, Relli V, Palloni A, Vasuri F, Malvi D, Degiovanni A, et al. Mutant p53 Associates with Human Equilibrative Nucleoside 1 Upregulation and Better Response to Adjuvant Gemcitabine in Intrahepatic Cholangiocarcinoma Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115259
BibTeX
@article{Deserti2025,
author = {Deserti, Marzia and Relli, Valeria and Palloni, Andrea and Vasuri, Francesco and Malvi, Deborah and Degiovanni, Alessio and Rimedio, Simone and Delbaldo, Chiara and Deiana, Chiara and Brandi, Giovanni and Tavolari, Simona},
title = {Mutant p53 Associates with Human Equilibrative Nucleoside 1 Upregulation and Better Response to Adjuvant Gemcitabine in Intrahepatic Cholangiocarcinoma Patients},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26115259}
}
EUVIMED